Leadership

Mr. Buchi is currently the chairman of the board of directors at Dicerna Pharmaceuticals and a director of Amneal Pharmaceuticals and Benitec Biopharma Ltd. Mr. Buchi was most recently president and chief executive officer at TetraLogic Pharmaceuticals from 2012 to 2016. Previously, he served as Impax Laboratories' interim President and chief executive officer from December 2016 to March 2017. Earlier, he served as corporate vice president of Global Branded Products at Teva Pharmaceutical from 2011 to May 2012. Mr. Buchi also served as chief executive officer of Cephalon, which was acquired by Teva in October 2011. He had been at the company since 1991. Mr. Buchi holds a Masters of Management degree from the J.L. Kellogg Graduate School of Management from Northwestern University and a B.A. in Chemistry from Cornell University.

Dr. Ron Law, Ph.D., was previously the Chief Strategy Officer of Oramed Pharmaceuticals Inc., where he was responsible for the development and execution of scientific and business collaborations and partnerships, as well as the identification of new targets and indications for its platform drug delivery technology and pipeline expansion. Prior to Oramed, Dr. Law was a scientific consultant in oncology at Third Coast therapeutics, a diabetes consultant at Doctor Evidence and a Medical Affairs consultant at PharmaIN. Previously, he held several leadership and strategic roles at Takeda Pharmaceuticals International, spanning US Medical Affairs, Global Medical Affairs, Corporate Strategic Planning, Global Scientific Affairs and Intelligence, and R&D External Innovation. Prior to joining Takeda, Dr. Law was an Associate Professor of Medicine in the Division of Endocrinology, Diabetes and Hypertension at the David Geffen School of Medicine at UCLA. Dr. Law received a Ph.D. in Molecular Biology from University of California at Los Angeles and a J.D. from the Whittier College School of Law, and both an M.S. and B.S. in Biological Sciences from the University of Illinois at Chicago. He is a member of the American Diabetes Association and the American Heart Association.

Mr. Caldwell has been a financial adviser and consultant for BioSpecifics for 12 years. Previously, he was the Vice President of Finance and Controller at PDL BioPharma (formerly Protein Design Labs) and later became a business and financial consultant for the company. Prior to joining PDL in 1992, Mr. Caldwell was the Controller at Meta-Software, Inc. He holds a B.S. in Finance from San Jose State University.

Mr. Hutchison most recently served as the Chief Financial Officer of SwanBio Therapeutics, a private gene therapy biotech company. Before SwanBio, Mr. Hutchison served as the Chief Financial Officer of Innocoll, Inc., a private biotech company. Prior to that, Mr. Hutchison served as the Chief Financial Officer of TetraLogic Pharmaceuticals, a public biotech company, and was formerly Vice President – Finance before assuming his role as CFO. Before that, Mr. Hutchison was Teleflex, Inc.’s Vice President – Corporate Controller and Chief Accounting Officer. Before his time at Teleflex, Mr. Hutchison was Vice President – Group Controller of Cephalon, Inc., an international biopharmaceutical company. Mr. Hutchison received his B.S. degree in Accounting from the Wharton School of the University of Pennsylvania (UPenn) and also earned a B.A. degree in Psychology from UPenn.